United Biomedical Inc Asia (聯亞生技) on Sunday urged the government to give its COVID-19 vaccine candidate, UB-612, a second chance, after its application for emergency use authorization (EUA) was denied last week.
Company founder Wang Chang-yi (王長怡) said that the Food and Drug Administration’s (FDA) standards for granting an EUA were hastily devised and outdated.
In assessing the effectiveness of a vaccine candidate, the FDA only considers the virus neutralizing antibodies — expressed as geometric mean titers (GMTs) — but the reaction of T-cells should also be part of the equation, Wang said.
Photo: CNA
The FDA should compare the effectiveness of the UB-612 vaccine and the AstraZeneca vaccine against the Delta variant of SARS-CoV-2, given that the variant is the most contagious, she said.
“It would be deeply regrettable to deny people access to such a good vaccine because of hastily devised EUA standards,” Wang said.
Despite the setback, the firm remains committed to seeking international approval for its COVID-19 vaccine candidate, she said.
United Biomedical said that it would soon appeal the FDA’s decision not to grant an EUA for the UB-612 vaccine.
The FDA respects the company’s right to appeal, it said, adding that it would review the application and decide whether another meeting of experts would be necessary.
On Monday last week, the FDA said that a majority of the experts had on Sunday voted not to grant the company an EUA.
To be granted an EUA, a vaccine must have a seroconversion rate of more than 50 percent, with GMTs at least equal to two-thirds of the level found in recipients of the AstraZeneca vaccine.
The FDA decided to test the antibody concentrations against people who had been inoculated with the AstraZeneca vaccine, because there is no globally recognized method for measuring GMTs or an accepted standard for what GMT level indicates effective protection.
The interim results of the company’s phase 2 clinical trials, released in late June, show that participants in the 19 to 64 age group had a seroconversion rate of 95.65 percent, meaning that 95.65 percent of participants produced neutralizing antibodies.
At the time, the company said that the GMT level was 102.3, while the GMT level of the AstraZeneca vaccine was 187.9, according to the FDA.
The comany had said that it would continue its phase 2 clinical trials in Taiwan and that its parent company, United Biomedical Inc, would re-evaluate the benefits of conducting phase 3 clinical trials.
At Sunday’s news conference, Wang did not say whether the company was proceeding with its plan to begin phase 2/3 efficacy trials in India, which were expected to have 11,000 participants.
The company would conduct phase 3 clinical trials in India for its “next-generation” COVID-19 vaccine, named “UB-613,” she said, without elaborating.
SECOND-RATE: Models distilled from US products do not perform the same as the original and undo measures that ensure the systems are neutral, the US’ cable said The US Department of State has ordered a global push to bring attention to what it said are widespread efforts by Chinese companies, including artificial intelligence (AI) start-up DeepSeek (深度求索), to steal intellectual property from US AI labs, according to a diplomatic cable. The cable, dated Friday and sent to diplomatic and consular posts around the world, instructs diplomatic staff to speak to their foreign counterparts about “concerns over adversaries’ extraction and distillation of US AI models.” Distillation is the process of training smaller AI models using output from larger, more expensive ones to lower the costs of training a powerful new
Shares of Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) have repeatedly hit new highs, but an equity analyst said the stock’s valuation remains within a reasonable range and any pullback would likely be technical. The contract chipmaker’s historical price-to-earnings (P/E) ratio has ranged between 20 and 30, Cathay Futures Consultant Co (國泰證期) analyst Tsai Ming-han (蔡明翰) told Central News Agency. With market consensus projecting that TSMC would post earnings per share of about NT$100 (US$3.17) this year, supported by strong global demand for artificial intelligence (AI) applications, and the stock currently trading at a P/E ratio of below 25, Tsai said the valuation
The artificial intelligence (AI) boom has triggered a seismic reshuffling of global equity markets, with Taiwan and South Korea muscling past European nations one by one. With its stock market now valued at nearly US$4.3 trillion, Taiwan surpassed the UK, Europe’s biggest market, earlier this month, data compiled by Bloomberg showed. South Korea is about US$140 billion away from doing the same. The tech-heavy Asian markets have shot past Germany and France in the past seven months. The shift is largely down to massive gains in shares of three companies that provide essential hardware for AI: Taiwan Semiconductor Manufacturing Co (TSMC, 台積電),
The US Department of Commerce last week ordered multiple chip equipment companies to halt shipments of certain tools to China’s second-largest chipmaker, Hua Hong Semiconductor Ltd (華虹半導體), its latest action to slow the country’s development of advanced chips, two people familiar with the matter said. The department sent letters to at least a handful of companies informing them of restrictions on tools and other materials destined for two Hua Hong facilities US officials believe make China’s most sophisticated chips, the people said. Top US chip equipment companies Lam Research Corp, Applied Materials Inc and KLA Corp, each of which has significant
RSS